MEA Syringes Market

MEA Syringes Market Size (2023 to 2028)

The syringes market size in the Middle East and Africa is estimated to be worth USD 2.15 billion by 2028 from USD 1.61 billion in 2023, growing at a CAGR of 5.98% from 2023 to 2028.

The growth of the market is driven by factors such as the increasing number of chronic diseases and infectious diseases such as malaria, dengue, diabetes, cardiovascular diseases, and typhoid fever in adults and children, and greater adoption of injectable drugs is expected to increase the demand for syringes in the near future. Chronic and infectious diseases require continuous diagnosis through various medical tests that require the use of syringes. According to the WHO (World Health Organization), cancer cases worldwide will reach 25 million in 2025. Between 2020 and 2040, the number of patients requiring first-line chemotherapy worldwide each year is expected to increase by 50%. The demand for chemotherapy will mainly be the result of population growth and expected variations in the spread of cancer, which is expected to increase the need for syringes in the near future. According to the International Diabetes Federation, approximately 465 million people worldwide will have diabetes in 2020, resulting in 4.5 million deaths each year. Therefore, the launch of new injectable drugs will play an essential role in driving the market.

Older people are more prone to chronic lifestyle disorders, while children are more affected by acute diseases and accidents. Therefore, the number of tests and treatments performed has increased as patients and seniors susceptible to chronic diseases increase. As a result, the demand and use of syringes are growing. Diabetes is more common in Saudi Arabia, Bahrain, Oman, and Qatar owing to various risk factors like sedentary lifestyle, unhealthy diets, and genetic predisposition. This has led to an increase in the number of people with diabetes to double to 2.4 million by 2040. Many of these patients are advised of regular health check-ups and intravenous insulin administration, which increases the demand for syringes in the MEA region.

Several advances in the medical field have seen development in pre-filled ready-to-use syringes, metered-dose syringes for hormone therapies, insulin and derma fillers, etc. are projected to drive the MEA syringes market during the forecast period.

Unsafe practices, such as multiple uses of syringe and needle and lack of preventive measures by healthcare professionals, leads to needle stick injuries. Needle prick injuries pose a risk for infections. Over time, approximately 34,000 HIV infections, 316,000 hepatitis C transmissions, and 1.82 million hepatitis B infections per year were reported worldwide. These needle prick injuries and the availability of alternatives such as patches, pills, etc., are expected to restrain the market growth.

This research report on the Middle East and Africa syringes market has been segmented and sub-segmented into the following categories:

By Usability:

• Sterilizable/reusable
  • Hypodermic
  • Oral
• Disposable Syringes
  • Conventional
  • Safety
  • Prefilled

By Material:

• Glass Syringes
• Plastic Syringes

By Type:

• General Syringes
• Specialized Syringes
  • Insulin
  • Tuberculin
  • Allergy
  • Others

By Country: 

• KSA
• UAE
• Israel
• rest of GCC countries
• South Africa
• Ethiopia
• Kenya
• Egypt
• Sudan
• rest of MEA

Middle East is expected to dominate the MEA syringes market. In 2020, UAE led the MEA market with a market share of over 35%. This market growth is mainly due to the increase in cancer cases, the high rate of diabetes, and the early adoption of the latest healthcare equipment. In the United Arab Emirates, the prevalence of diabetes is increased. According to the International Diabetes Federation, 18.2% of the UAE population between the ages of 20 and 79 have type 2 diabetes, amounting to more than one million people in the region. In addition, with an increasing number of cancer cases, the demand for syringes is also increasing due to their predominant use in health care for various cancers such as breast cancer, lung cancer, cervical cancer, and prostate cancer, among others.

The regional market in Saudi Arabia is notable, mainly because of large companies in the region, more infectious diseases, increasing prevalence of chronic and lifestyle-related diseases, and increased awareness of specialized syringes. For example, according to the Ministry of Health, nearly 47,000 cases of infectious diseases were found in the region in 2018. Many of these infectious diseases are treated with injectable vaccines, increasing the demand for syringes.

KEY MARKET PLAYERS:

Becton, Dickinson and Company, Terumo Corporation, Medtronic plc, Smiths Medical, B. Braun Medical Inc., NIPRO Corporation, Hindustan Syringes & Medical Devices Limited, Gerresheimer AG, SCHOTT AG, and CODAN Medizinische Geräte GmbH & Co KG are some of the key players operating in the Middle East and Africa syringes market.